首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Formulation and Evaluation of Extended Release Floating Matrix Tablet of Eperisone Hydrochloride by Direct Compression Method
【24h】

Formulation and Evaluation of Extended Release Floating Matrix Tablet of Eperisone Hydrochloride by Direct Compression Method

机译:直接压缩法制备盐酸盐延长剥离浮料组片剂的制定与评价

获取原文
获取外文期刊封面目录资料

摘要

Increased complications and costs of marketing of innovative drugs focused greater attention to the development of sustained release (SR) or controlled release (CR) drug delivery systems. Delivery systems extended release or controlled release rate can achieve predictable and reproducible, the extended duration of activity for the short time of life - drugs, reduced toxicity and dose reduction request, the optimized therapy and better patient compliance. It is controlled primarily by the type and the proportion of the polymers used in the preparation. Eperisone hydrochloride is a centrally acting muscle relaxant acting through poly and mono-synaptic reflexes in the spinal cord, exhibits vasodilator effect, increases blood flow and inhibits the pain reflex pathway. The objective of present work was to develop and evaluated oral extended release floating matrix tablet of eperisone HCl prepared by the method of direct compression, using hydroxy propyl methyl cellulose (HPMC K15, HPMC K4) and PVP K30 as matrix formation polymers. Sodium bicarbonate and citric acid was used as gas generating agents. The FTIR spectra of the eperisone HCl and other excipients alone and in combination show the compatibility of the drug and excipients. Nine formulations of different polymer percentages were formulated (F1-F9). Pre-compression parameters were evaluated. The influence of matrix forming agents and binary mixtures of them on eperisone HCl release was investigated. The formulated tablets were characterized by thickness and diameter, drug content, hardness, friability, uniformity of weight, In vitro buoyancy studies and dissolution rate studies. The formulated tablets had acceptable physicochemical characters. The data obtained from the in-vitro dissolution studies of optimized batch F7 were fitted in different models. The optimized formulation F7 showed 99.45±0.45% drug content and floating lag times of 65±4 sec. Drug release mechanism was found to be first order kinetics. Eperisone HCl floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic effect of the drug.
机译:创新药物营销的复杂性和成本增加,更加注重持续释放(SR)或控释(CR)药物递送系统的开发。递送系统扩展释放或受控释放率可以实现可预测和可重复的,延长寿命短时的活动持续时间 - 药物,减少毒性和剂量减少要求,优化治疗和更好的患者遵守。它主要受到制剂中使用的聚合物的类型和比例的控制。盐酸盐酸盐是一种中央作用的肌肉松弛剂,其通过脊髓中的聚碳和单突触反射作用,表现出血管扩张效果,增加血液流动并抑制疼痛反射途径。目前工作的目的是通过直接压缩方法,使用羟基丙基甲基纤维素(HPMC K15,HPMC K4)和PVP K30作为基质形成聚合物,通过直接压缩方法制备和评估口服延长释放浮动基质片剂。碳酸氢钠和柠檬酸用作气体发生剂。单独的ePerisone HCl和其他赋形剂的FTIR光谱和组合表明药物和赋形剂的相容性。配制了九种不同聚合物百分比的制剂(F1-F9)。评估预压缩参数。研究了基质形成剂及其二元混合物对Eperisone HCl释放的影响。配制片剂的特征在于厚度和直径,药物含量,硬度,脆性,重量均匀,体外浮力研究和溶出速率研究。配制的片剂具有可接受的物理化学特性。从优化的批量F7的体外溶解研究中获得的数据被装配在不同的模型中。优化的配方F7显示出99.45±0.45%的药物含量和65±4秒的浮动滞后时间。发现药物释放机制是第一阶动力学。 Eperisone HCl浮动片剂随着药物的生物利用度和治疗效果而显示出胃停留时间增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号